Clinical trials
Immunotherapy clinical trials
Below are recruiting immunotherapy clinical trials, each written for real people, not researchers. We’re tracking 747 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06339060RecruitingPhase 3
Chemoradiation and immunotherapy to save the esophagus
This trial tests whether adding immunotherapy to standard chemoradiation (chemotherapy plus radiation) can help preserve the esophagus and avoid surgery in people with resectable esophageal cancer. It aims to see if this combination is safer and more effective than current treatment.
ShanghaiAges 18–75 - NCT06492408RecruitingPhase 2
Immunotherapy before surgery for liver cancer
This trial tests giving two immunotherapy drugs directly into the tumor before surgery for liver cancer. It aims to see if this approach can shrink the tumor and improve outcomes for patients who are candidates for surgery.
Guanzhou, GuangdongAges 18–75 - NCT06492421RecruitingPhase 2
Immunotherapy before surgery for lung cancer
This trial tests whether giving two immunotherapy drugs directly into the tumor before surgery can shrink non-small cell lung cancer and improve outcomes. It is for people with early-stage (IIIA) lung cancer who are candidates for surgery.
Guanzhou, GuangdongAges 18–75 - NCT07815834RecruitingPhase 3
FAPI-guided radiation with cadonilimab and chemo for colorectal cancer spread to the abdomen
This trial tests a new combination treatment for colorectal cancer that has spread only to the lining of the abdomen (peritoneum). It combines targeted radiation, an immunotherapy drug called cadonilimab, and standard chemotherapy to see if it can help control the disease better than current options.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06272214RecruitingPhase 2
Adjuvant radiotherapy for esophageal cancer after immunotherapy
This trial tests if adding radiation therapy after surgery improves outcomes for people with esophageal squamous cell cancer who received immunotherapy and chemotherapy before surgery but did not achieve a complete response. It aims to see if this approach can lower the chance of the cancer coming back.
Hangzhou, ZhejiangAges 18–75 - NCT06413342RecruitingPhase 2
Sintilimab after chemoradiation for older adults with esophageal cancer
This trial tests whether the immunotherapy drug Sintilimab can help prevent esophageal cancer from returning after standard chemotherapy and radiation. It is for patients aged 70-85 who cannot have or choose not to have surgery.
Hangzhou, ZhejiangAges 70–85 - NCT04837859RecruitingPhase 2
Personalized immunotherapy for early-stage unfavorable Hodgkin lymphoma
This trial studies a customized immune-based treatment approach for people with early-stage “unfavorable” classical Hodgkin lymphoma who have not had prior treatment. It may help by targeting your lymphoma using an individualized plan based on your case.
CologneAges 18 years+ - NCT07799922Recruiting
Liver cancer treatment after immunotherapy
This trial tests a new procedure called IRE (a way to destroy tumors) for people with liver cancer that has not responded well to initial immunotherapy. It aims to help when surgery is not possible due to the tumor's size or location.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06535087Recruiting
How airway allergies affect children and parents' quality of life
This study looks at how airway allergies (like asthma and hay fever) affect the daily life of children and their parents. By filling out a questionnaire, you can help researchers understand these challenges and find better ways to support families.
Shanghai, Shanghai MunicipalityAges 5–16 - NCT07779018RecruitingPhase 2
CAR-T cell therapy after second-line treatment for aggressive B-cell lymphoma
This trial tests a type of immunotherapy called CAR-T cell therapy, which uses your own immune cells to fight lymphoma. It is for people who have already responded well to a second round of chemotherapy and are at high risk of the cancer coming back. The goal is to see if this treatment can keep the cancer away longer.
BeijingAges 18–85 - NCT07775950Recruiting
Monitoring and treating colorectal cancer based on tumor DNA
This study looks at using a blood test to find cancer DNA and guide treatment for people with stage IV colorectal cancer that has a specific genetic pattern. The goal is to see if this approach can help monitor the cancer and personalize treatment.
Guangzhou, GuangdongAges 18 years+ - NCT07780838RecruitingPhase 2
Combination therapy for advanced bile duct cancer with an FGFR2 change
This study tests a combination of two chemotherapy drugs (gemcitabine and cisplatin) with an immunotherapy drug (durvalumab), alternating with a targeted therapy (pemigatinib) for people with advanced biliary tract cancer that has an FGFR2 gene change. The goal is to see if this treatment sequence helps control the cancer.
Columbus, OhioAges 18 years+ - NCT07775820Recruiting
Retrying immunotherapy after lung inflammation
This trial looks at whether people with lung cancer who had lung inflammation from immunotherapy can safely try immunotherapy again. It aims to see if restarting treatment helps without causing severe side effects.
Guangzhou, GuangdongAges 18 years+ - NCT07782632Recruiting
Imaging scans to predict immunotherapy response in liver cancer
This study looks at how doctors can use imaging scans to predict how well immunotherapy will work for people with liver cancer that cannot be removed by surgery. Participants must have already received immunotherapy and have had baseline scans.
Hefei, AnhuiAges 18–75 - NCT06541327Recruiting
Cell therapy for returning lymphoma study
This study collects data from adults with lymphoma that has come back or not improved after treatment, who have received or are receiving special cell therapies. The goal is to learn more about how these treatments work in real life.
ShanghaiAges 18 years+ - NCT06562920RecruitingPhase 2
Immunotherapy plus chemo and SBRT before surgery for limited-stage small cell lung cancer
This trial tests a combination of immunotherapy (adebrelimab), chemotherapy, and targeted radiation (SBRT) before surgery for people with limited-stage small cell lung cancer. The goal is to see if this approach can shrink tumors and improve outcomes before the main treatment.
Hangzhou, ZhejiangAges 18–75 - NCT07770100RecruitingPhase 2
Matching immunotherapy and targeted radiation for advanced cancer
This trial tests combining immunotherapy (a treatment that boosts your immune system to fight cancer) with a targeted type of radiation called SBRT, which precisely delivers high-dose radiation to multiple cancer spots. The main goal is to see if this combination helps control metastatic cancer (cancer that has spread) better than standard care.
Lexington, KentuckyAges 18–99 - NCT06041477RecruitingPhase 3
Combining treatments for liver cancer before surgery
This study tests whether giving targeted therapy and immunotherapy at the same time or one after the other is better for shrinking liver tumors that can't be removed right now but might be removable after treatment.
Guangzhou, GuangdongAges 18–75 - NCT06572514RecruitingPhase 1/Phase 2
Lower radiation after chemo-immunotherapy for head and neck cancer
This trial tests if giving less radiation than usual is safe and effective for certain head and neck cancers after initial treatment with chemotherapy and immunotherapy. It aims to reduce side effects while still controlling the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06574698Recruiting
Adding Naxitamb to high-risk neuroblastoma treatment
This trial is for children with high-risk neuroblastoma, a type of nerve cell cancer. It tests adding a new medicine called Naxitamb to standard induction therapy to see if it works better. High-risk means the cancer is advanced or has certain aggressive features.
Guanzhou, GuangdongAges 1–21 - NCT06342037RecruitingPhase 2
New immunotherapy options for advanced triple-negative breast cancer
This trial tests two immunotherapy drugs (atezolizumab and tiragolumab) for people with advanced triple-negative breast cancer that has not responded to standard treatments. It aims to see if this combination can shrink or slow the cancer.
Amsterdam, North HollandAges 18 years+ - NCT07754812RecruitingPhase 4
Oral paclitaxel with immunotherapy and SBRT before surgery for older adults with lung cancer
This trial tests a new way to treat non-small cell lung cancer in people aged 70 or older. You will receive oral chemotherapy (paclitaxel) with immunotherapy and focused radiation (SBRT) before surgery, hoping to shrink the tumor and improve outcomes.
Guangzhou, GuangdongAges 70 years+ - NCT06510660RecruitingPhase 2
Immunotherapy and Chemoradiation for Advanced Esophageal Cancer
This trial tests a combination of immunotherapy (adebrelimab) plus standard chemotherapy and radiation for people with advanced esophageal cancer that cannot be removed by surgery. The goal is to see if adding the immunotherapy before and during chemoradiation helps control the cancer better.
Fuzhou, FujianAges 18–70 - NCT06612632RecruitingPhase 1/Phase 2
Retrying Immunotherapy for Solid Tumors After First Trial
This trial tests whether giving immunotherapy again can help people with solid tumors who have already tried an experimental treatment in a clinical trial and it stopped working. It looks for patients whose cancer has returned or spread and who can start the new treatment within 12 weeks of their last therapy.
BeijingAges 18 years+
Hear when a new Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for immunotherapy?
- Yes. Clin2 currently lists 747 recruiting immunotherapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a immunotherapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a immunotherapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.